Rhumbline Advisers increased its position in shares of Prothena Co. PLC (NASDAQ:PRTA) by 44.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 57,416 shares of the biotechnology company’s stock after acquiring an additional 17,569 shares during the period. Rhumbline Advisers owned approximately 0.14% of Prothena worth $591,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently bought and sold shares of PRTA. Marshall Wace LLP purchased a new stake in shares of Prothena in the 3rd quarter valued at $191,000. Nisa Investment Advisors LLC boosted its stake in shares of Prothena by 7,725.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 19,955 shares of the biotechnology company’s stock valued at $206,000 after purchasing an additional 19,700 shares in the last quarter. Trexquant Investment LP purchased a new stake in shares of Prothena in the 3rd quarter valued at $301,000. Paloma Partners Management Co purchased a new stake in shares of Prothena in the 3rd quarter valued at $349,000. Finally, Russell Investments Group Ltd. boosted its stake in shares of Prothena by 61.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 51,711 shares of the biotechnology company’s stock valued at $676,000 after purchasing an additional 19,647 shares in the last quarter.
A number of equities research analysts have recently issued reports on the stock. BidaskClub raised shares of Prothena from a “hold” rating to a “buy” rating in a research note on Saturday. Zacks Investment Research raised shares of Prothena from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research note on Monday, February 4th. Finally, Cantor Fitzgerald assumed coverage on shares of Prothena in a research note on Monday, March 4th. They issued an “overweight” rating and a $13.77 price objective for the company. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and five have issued a buy rating to the stock. Prothena has an average rating of “Hold” and an average target price of $35.75.
Prothena (NASDAQ:PRTA) last announced its quarterly earnings results on Thursday, February 14th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.04). The firm had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.28 million. Prothena had a negative net margin of 16,297.91% and a negative return on equity of 37.78%. As a group, equities research analysts expect that Prothena Co. PLC will post -2.44 earnings per share for the current fiscal year.
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis.
Recommended Story: Understanding Compound Annual Growth Rate (CAGR)
Want to see what other hedge funds are holding PRTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prothena Co. PLC (NASDAQ:PRTA).
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.